An anti-HIV drug combination, Truvada, plus prevention strategies can reduce the risk of healthy adolescents at risk for acquiring HIV. The Food and Drug Administration has approved the drug combination for HIV prevention treatment for adolescents 15 years and older.

The research for this pre-exposure prophylaxis, or PrEP, was supported by Westat. Westat provided full-service support for this study through the Adolescent Trials Network for HIV/AIDS Interventions (ATN) – ATN  protocol 113.  The Eunice Kennedy Shriver National Institute of Child Health and Human Development funds ATN research.